Skip to main content
TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as SecondLine Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma Morschhauser, F., Dahiya, S., Palomba, M., Garcia-Sancho, A., Reguera, J., Kuruvilla, J., Jaeger, U., Cartron, G., Izutsu, K., Dreyling, M., Kahl, B. S., Ghesquieres, H., Ardeshna, K., Goto, H., Barbui, A., Abramson, J. S., Borchmann, P., Fleury, I., Mielke, S., Skarbnik, A., de Vos, S., Kamdar, M., Karmali, R., Viardot, A., Farazi, T., Fasan, O., Lymp, J., Vedal, M., Nishii, R., Avilion, A., Papuga, J., Nastoupil, L. J. AMER SOC HEMATOLOGY. 2023

View details for DOI 10.1182/blood-2023-179474

View details for Web of Science ID 001159306702115